US Patent

US10857212 — Augmented acid alpha-glucosidase for the treatment of Pompe disease

Method of Use · Assigned to Amicus Therapeutics Inc · Expires 2037-08-12 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

A method for treating Pompe disease involves administering a combination of recombinant human acid alpha-glucosidase and miglustat.

USPTO Abstract

A method for treating Pompe disease including administration of recombinant human acid Î±-glucosidase having optimal glycosylation with mannose-6-phosphate residues in combination with an amount of miglustat effective to maximize tissue uptake of recombinant human acid Î±-glucosidase while minimizing inhibition of the enzymatic activity of the recombinant human acid Î±-glucosidase is provided.

Drugs covered by this patent

Zavesca (MIGLUSTAT) · AstraZeneca

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3726`	—	Zavesca

Patent Metadata

Patent number: US10857212
Jurisdiction: US
Classification: Method of Use
Expires: 2037-08-12
Drug substance claim: No
Drug product claim: No
Assignee: Amicus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.